Methylation status of TUSC3 is a prognostic factor in ovarian cancer

Cancer

Volumn 119, Issue 5, 2013, Pages 946-954

  Pils, Dietmar ^a,b   Horak, Peter ^b   Vanhara, Petr ^b   Anees, Mariam ^b   Petz, Michaela ^b   Alfanz, Angela ^b   Gugerell, Alfred ^b   Wittinger, Michael ^b   Gleiss, Andreas ^b   Auner, Veronika ^a,b   Tong, Dan ^a,b   Zeillinger, Robert ^b   Braicu, Elena Ioana ^c   Sehouli, Jalid ^c   Krainer, Michael ^b  

^a Division of Gynecology   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biomarker.; glycosylation; methylation; ovarian cancer; overall survival; progression free survival; TUSC3

Indexed keywords

MESSENGER RNA; TUMOR SUPPRESSOR CANDIDATE 3 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; GLYCOSYLATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RNA ANALYSIS; TUSC3 GENE;

ADULT; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84874248416     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27850     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 2006; 12: 2788-2794.
3. Campan M, Moffitt M, Houshdaran S, et al. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer [serial online]. PLoS One. 2011; 6: e28141.
4. Gloss BS, Patterson KI, Barton CA, et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett. 2012; 318: 76-85.
5. Das PM, Singal R,. DNA methylation and cancer. J Clin Oncol. 2004; 22: 4632-4642.
6. Jones PA, Baylin SB,. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3: 415-428.
7. Laird PW,. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3: 253-266.
8. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB,. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35: 46-54.
9. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R,. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996; 35: 55-65.
10. Bashyam MD, Bair R, Kim YH, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005; 7: 556-562.
11. Levy A, Dang UC, Bookstein R,. High-density screen of human tumor cell lines for homozygous deletions of loci on chromosome arm 8p. Genes Chromosomes Cancer. 1999; 24: 42-47.
12. Arbieva ZH, Banerjee K, Kim SY, et al. High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22. Genome Res. 2000; 10: 244-257.
13. Bova GS, Carter BS, Bussemakers MJ, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 1993; 53: 3869-3873.
14. Pils D, Horak P, Gleiss A, et al. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 2005; 104: 2417-2429.
15. Garshasbi M, Hadavi V, Habibi H, et al. A defect in the TUSC3 gene is associated with autosomal recessive mental retardation. Am J Hum Genet. 2008; 82: 1158-1164.
16. Molinari F, Foulquier F, Tarpey PS, et al. Oligosaccharyltransferase- subunit mutations in nonsyndromic mental retardation. Am J Hum Genet. 2008; 82: 1150-1157.
17. Kelleher DJ, Gilmore R,. An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology. 2006; 16: 47R-62R.
18. Kelleher DJ, Karaoglu D, Mandon EC, Gilmore R,. Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties. Mol Cell. 2003; 12: 101-111.
19. Schulz BL, Stirnimann CU, Grimshaw JP, et al. Oxidoreductase activity of oligosaccharyltransferase subunits Ost3p and Ost6p defines site-specific glycosylation efficiency. Proc Natl Acad Sci U S A. 2009; 106: 11061-11066.
20. Collard JG, Schijven JF, Bikker A, La Riviere G, Bolscher JG, Roos E,. Cell surface sialic acid and the invasive and metastatic potential of T-cell hybridomas. Cancer Res. 1986; 46: 3521-3527.
21. Dennis JW, Granovsky M, Warren CE,. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999; 1473: 21-34.
22. Yogeeswaran G, Salk PL,. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science. 1981; 212: 1514-1516.
23. Janik ME, Litynska A, Vereecken P,. Cell migration-the role of integrin glycosylation. Biochim Biophys Acta. 2010; 1800: 545-555.
24. Kakugawa Y, Wada T, Yamaguchi K, et al. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci U S A. 2002; 99: 10718-10723.
25. Lau KS, Partridge EA, Grigorian A, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007; 129: 123-134.
26. Fang M, Shen Z, Huang S, et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell. 2010; 143: 711-724.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005; 41: 1690-1696.
28. Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005; 3: 335-343.
29. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004; 10: 3441-3454.
30. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR [serial online]. Nucleic Acids Res. 2001; 29: e45.
31. Holschneider CH, Berek JS,. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000; 19: 3-10.
32. van der Burg ME,. Advanced ovarian cancer. Curr Treat Options Oncol. 2001; 2: 109-118.
33. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11: 719-725.
34. Birrer MJ,. The origin of ovarian cancer-is it getting clearer? N Engl J Med. 2010; 363: 1574-1575.
35. Ahmed A, Becker C, Bast R. Jr, The origin of ovarian cancer. BJOG. 2012; 119: 134-136.
36. Karaoglu D, Kelleher DJ, Gilmore R,. Functional characterization of Ost3p. Loss of the 34-kD subunit of the Saccharomyces cerevisiae oligosaccharyltransferase results in biased underglycosylation of acceptor substrates. J Cell Biol. 1995; 130: 567-577.
37. Zhou H, Clapham DE,. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. Proc Natl Acad Sci U S A. 2009; 106: 15750-15755.
38. Hakomori S,. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002; 99: 10231-10233.
39. Kobata A, Amano J,. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol Cell Biol. 2005; 83: 429-439.
40. Saldova R, Dempsey E, Perez-Garay M, et al. 5-AZA-2′-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics. 2011; 6: 1362-1372.
41. Matei D, Fang F, Shen C, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 2012; 72: 2197-2205.
42. Beretta GL, Benedetti V, Cossa G, et al. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol. 2010; 79: 1108-1117.